Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Could The Biosimilar Market Stall Before it Ever Really Started?

Key clinical point: Regulatory hurdles are currently stifling biosimilar adoption.

Major finding: Industry stakeholders have yet to recognize the value biosimilars bring.

Study details: An expert presentation on status of the biosimilar market in the United States.

Disclosures: Ms. Woollett disclosed no conflicts of interest relevant to her presentation.

Citation:

Woollet G et al. AMCP NEXUS 2019, Session D4.